Dr. Horn on Monitoring Response and Resistance to Ensartinib in ALK+ NSCLC
Posts by :
The Xcovery team will be attending American Society of Clinical Oncology (ASCO) in Chicago, Illinois on May 31 – June 4, 2019. Please email Olivia@xcovery.com if you would like to schedule time to meet with the team. We hope to see you there!
Xcovery Announces First Cohort of Patients Dosed in a Phase 1/2 Clinical Trial of Vorolanib in Combination with Nivolumab for Treatment of Non-small Cell Lung Cancer or Thymic Carcinoma
Palm Beach Gardens, Fla., July 31, 2018 – Xcovery, a developer of targeted therapeutics for cancer, today announced that the first cohort of patients has been enrolled to the Phase 1/2 clinical trial evaluating the safety and efficacy of the combination of vorolanib (X-82) and nivolumab (Opdivo®) for the treatment of non-small cell lung cancer […]
Ensartinib in Melanoma Press Release. Please click on the link below for details. You can find more information on this and other Ensartinib trials on the clinicaltrials.gov website.
Xcovery Announces Initiation of Phase 2 Clinical Trial for Ensartinib in Melanoma Patients with ALK Alternations